Commonwealth Equity Services’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Commonwealth Equity Services’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$144K	Hold	61,412	–	–	﹤0.01%	4082
2025 Q4	$82.9K	Buy	61,412 +425	+0.7%	+$619	﹤0.01%	4133
2025 Q3	$92K	Hold	60,987	–	–	﹤0.01%	4100
2025 Q2	$71K	Buy	60,987 +300	+0.5%	+$396	﹤0.01%	4120
2025 Q1	$96K	Sell	60,687 -3,258	-5%	-$7.03K	﹤0.01%	4000
2024 Q4	$194K	Hold	63,945	–	–	﹤0.01%	3773
2024 Q3	$235K	Buy	63,945 +3,250	+5%	+$11.8K	﹤0.01%	3562
2024 Q2	$248K	Sell	60,695 -200	-0.3%	-$2.23K	﹤0.01%	3476
2024 Q1	$960K	Buy	60,895 +6,640	+12%	+$91.3K	﹤0.01%	2270
2023 Q4	$822K	Buy	54,255 +37,275	+220%	+$544K	﹤0.01%	2310
2023 Q3	$341K	Buy	16,980 +6,730	+66%	+$171K	﹤0.01%	2912
2023 Q2	$289K	Buy	+10,250	New	+$246K	﹤0.01%	3082

Other funds holding ZNTL

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $273M AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Commonwealth Equity Services's ZNTL Position: Q1 2026 in Review

Commonwealth Equity Services held its Zentalis Pharmaceuticals (ZNTL) position steady in Q1 2026 at 61,412 shares worth $144K. The position accounts for ﹤0.01% of the portfolio, ranked #4082.

Commonwealth Equity Services first reported a position in ZNTL in Q2 2023 and has held it in 12 quarters since. The position peaked at $960K in Q1 2024. 102 funds tracked by Wall St. Rank hold ZNTL as of Q1 2026.

Commonwealth Equity Services held 61,412 shares of Zentalis Pharmaceuticals worth $144K as of Q1 2026.
Commonwealth Equity Services left its Zentalis Pharmaceuticals share count unchanged in Q1 2026.
Zentalis Pharmaceuticals made up ﹤0.01% of Commonwealth Equity Services's portfolio in Q1 2026, its #4082 holding.
Commonwealth Equity Services first reported a position in Zentalis Pharmaceuticals in Q2 2023 and has held it in 12 quarters since.
Commonwealth Equity Services's Zentalis Pharmaceuticals position peaked at $960K in Q1 2024.
102 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2026.

Based on Commonwealth Equity Services's 13F filing for Q1 2026, filed 27 Apr 2026.